A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

EARLY_PHASE1UnknownINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 30, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Multiple Myeloma

Interventions

BIOLOGICAL

BCMA/CD19 dual-target CAR-T cell immunotherapy

The intervention is a CAR-T cell immunotherapy targeted CD19 and BCMA. The dosage ranges from 2×10\^5 to 1×10\^6 CAR+T/Kg.

Trial Locations (1)

Hebei Yanda Ludaopei Hospital, Sanhe